Ransdell Pierson –

Biogen, AbbVie drug slows MS episodes, safety issues recur

May 14, 2019 at 1:09 a.m.

By Ransdell Pierson (Reuters) - A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie...

Allergan rejects Valeant and Ackman’s raised takeover offer

August 25, 2021 at 12:37 a.m.

By Caroline Humer and Ransdell Pierson (Reuters) - The battle for botox maker Allergan Inc heated up on Tuesday as the company officially rejected a sweetened $53 billion takeover offer...

Merck to seek approval of osteoporosis drug, cites safety risks

May 14, 2019 at 1:00 a.m.

By Ransdell Pierson (Reuters) - Merck & Co said on Tuesday it plans to seek marketing approvals this year for an osteoporosis drug and a product to reverse the effects...

Big Pharma stands to profit by cleaning out its medicine chests

November 3, 2021 at 8:43 p.m.

NEW YORK (Reuters) - Leading global pharmaceutical companies have started to view their vast portfolios of older, established prescription drugs as vehicles for raising large sums of cash to fuel...

Big Pharma stands to profit by cleaning out its medicine chests

December 23, 2018 at 5:41 p.m.

NEW YORK (Reuters) - Leading global pharmaceutical companies have started to view their vast portfolios of older, established prescription drugs as vehicles for raising large sums of cash to fuel...

Pfizer’s weak drug pipeline fuels hunger for AstraZeneca

November 3, 2021 at 8:42 p.m.

NEW YORK (Reuters) - At the heart of Pfizer Inc's pursuit of British drugmaker AstraZeneca Plc is a shortage of attractive products in its own research pipeline, aggravated by a...

Pfizer’s weak drug pipeline fuels hunger for AstraZeneca

May 14, 2019 at 12:57 a.m.

NEW YORK (Reuters) - At the heart of Pfizer Inc's pursuit of British drugmaker AstraZeneca Plc is a shortage of attractive products in its own research pipeline, aggravated by a...

Lilly’s disappointing sales put focus on drug pipeline

August 24, 2021 at 11:16 p.m.

(Reuters) - Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs, and its shares fell more than 3 percent....

Abbott Laboratories profit beats forecast, but sales lag

August 24, 2021 at 11:03 p.m.

(Reuters) - Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday, but combined sales of its nutritional products, medical devices and generic medicines were slightly below Wall Street expectations. The...

Abbott Laboratories profit beats forecast, but sales lag

May 14, 2019 at 12:54 a.m.

(Reuters) - Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday, but combined sales of its nutritional products, medical devices and generic medicines were slightly below Wall Street expectations. The...

All Stories